Topical Melatonin Gel

About Pharmamel

Pharmamel is a clinical-stage biotech developing novel melatonin-based therapeutics for severe inflammatory and oxidative conditions. Its lead program targets sepsis, a life-threatening immune response to infection, and it holds a robust international patent portfolio covering formulations for sepsis, viral diseases, cancer, and mucositis. The company is currently in a pre-IPO phase, actively raising capital through a regulated platform to finance clinical development and pursue a public listing on the Spanish BME Scaleup market.

Therapeutic Areas